2 files

Supplementary Material: Infrequent Liver injury From Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma

posted on 02.03.2022, 09:53 by Robert J. Fontana, Irene Tsung, Ihab Kassab, Linnea Swanson, Francis P. Worden

Supplemental Figure 1. Patient survival after starting cemiplimab immunotherapy for advanced cSCC.

The overall patient survival in the 4 patients who developed liver injury was not significantly different versus those without liver injury. (p = 0.99 Kaplan‐Meier statistics).

Abbreviations: cSCC = cutaneous squamous cell carcinoma

Supplemental Table 1. Clinical characteristics and outcomes of solid organ transplants recipients with cutaneous squamous cell carcinoma receiving cemiplimab monotherapy.

Abbreviations: YO = year old; M = male, F = female; irAEs = immune related adverse events